Arsanis (NASDAQ:ASNS) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday.
A number of other analysts have also commented on the company. Zacks Investment Research lowered Arsanis from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. Piper Jaffray Companies decreased their price objective on Arsanis to $2.50 and set a “neutral” rating for the company in a report on Monday, August 13th. Finally, Citigroup downgraded Arsanis from a “buy” rating to a “neutral” rating in a report on Monday, July 9th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $14.88.
Shares of ASNS stock opened at $1.40 on Thursday. Arsanis has a 52 week low of $1.25 and a 52 week high of $28.69. The firm has a market capitalization of $18.90 million and a P/E ratio of -0.09. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 0.20.
Arsanis (NASDAQ:ASNS) last announced its quarterly earnings results on Monday, August 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.03). Sell-side analysts anticipate that Arsanis will post -2.46 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Granahan Investment Management Inc. MA bought a new position in Arsanis in the second quarter worth $365,000. BlackRock Inc. raised its holdings in Arsanis by 27.1% in the second quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock worth $812,000 after purchasing an additional 47,777 shares in the last quarter. California State Teachers Retirement System bought a new position in Arsanis in the first quarter worth $162,000. New York State Common Retirement Fund bought a new position in Arsanis in the first quarter worth $114,000. Finally, Northern Trust Corp bought a new position in Arsanis in the first quarter worth $735,000. Institutional investors and hedge funds own 68.70% of the company’s stock.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Read More: Dow Jones Industrial Average (DJIA)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.